GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » EV-to-Revenue

HLS Therapeutics (HLS Therapeutics) EV-to-Revenue : 2.76 (As of May. 01, 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HLS Therapeutics's enterprise value is $174.23 Mil. HLS Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $63.07 Mil. Therefore, HLS Therapeutics's EV-to-Revenue for today is 2.76.

The historical rank and industry rank for HLS Therapeutics's EV-to-Revenue or its related term are showing as below:

HLTRF' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.17   Med: 2.78   Max: 11.27
Current: 2.8

During the past 13 years, the highest EV-to-Revenue of HLS Therapeutics was 11.27. The lowest was -0.17. And the median was 2.78.

HLTRF's EV-to-Revenue is ranked worse than
56.98% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.32 vs HLTRF: 2.80

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), HLS Therapeutics's stock price is $3.56. HLS Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.96. Therefore, HLS Therapeutics's PS Ratio for today is 1.82.


HLS Therapeutics EV-to-Revenue Historical Data

The historical data trend for HLS Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics EV-to-Revenue Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.95 9.51 7.61 5.06 2.53

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.06 3.71 3.36 2.99 2.53

Competitive Comparison of HLS Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's EV-to-Revenue falls into.



HLS Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

HLS Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=174.233/63.074
=2.76

HLS Therapeutics's current Enterprise Value is $174.23 Mil.
HLS Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics  (OTCPK:HLTRF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

HLS Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3.56/1.955
=1.82

HLS Therapeutics's share price for today is $3.56.
HLS Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.96.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (HLS Therapeutics) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA 03-21-2013